EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China

Yue Li, Huan Yang, Song Tan, Lijun Luo, Xuebing Cao, JinQuan Hu, Bitao Bu, Ting Chang, Zhijun Li

Neurology and Therapy · 2026-08 · 15 (4) · 1973-1992

DOI: 10.1007/s40120-026-00977-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurology and Therapy, online erschienen am 10.06.2026. Verfasst von Yue Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder needing long-term immunosuppressive therapy. Eculizumab is a promising treatment, but real-world evidence on its efficacy and safety is limited.

Methods

This retrospective cohort study across six medical centers enrolled 60 patients with MG on eculizumab. Clinical data, including MG-Activities of Daily Living (MG-ADL) scores, quantitative MG scores (QMG), and oral corticosteroid dosage at baseline, weeks 1, 4, and 8, and final follow-up were obtained. Outcomes included score changes, post-intervention status (PIS), and safety profile.

Results

By week 8, 30.95% of patients achieved minimal manifestation status (MMS) or better, increasing to 32.69% at final follow-up. Mean ADL scores significantly dropped from 8.18 ± 3.99 at baseline to 5.59 ± 3.72 at week 1, 3.78 ± 3.42 at week 4, 3.50 ± 2.92 at week 8, and 3.33 ± 3.56 during final follow-up ( p < 0.0001). Clinically meaningful improvement (CMI) was observed in 56.9%, 70.0%, 85.0%, and 76.27% at the respective time points. Both thymoma-associated and non-thymoma subgroups showed significant ADL improvement ( p ≤ 0.026) with mixed-effects modeling revealing significant group × time interaction ( p = 0.01).The thymoma-associated MG (TAMG) group had a faster initial response, with subsequent outcomes comparable between the two groups. Among the 37 patients (61.67%) who switched from FcRn inhibitor therapy to eculizumab, clinical outcomes were non-inferior to those of direct eculizumab recipients and the magnitude of MG-ADL improvement was comparable to that of the overall treatment group. The mean daily corticosteroid dose decreased from 21.21 ± 13.68 mg at baseline to 13.32 ± 10.42 mg at final follow-up ( p < 0.0001) Adverse events were rare, with no treatment-related serious events.

Conclusion

Eculizumab provides rapid and sustained clinical improvement in patients with MG, with a favorable safety profile. Patients with TAMG show a faster initial response. For patients with an inadequate response to FcRn inhibitors, eculizumab remains an effective rescue strategy.

Schlagwörter

Stichwörter der Autor:innen

Clinical efficacyEculizumabMyasthenia gravisSteroid-sparing

Autor:innen und Institutionen

  • Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China.
  • Department of Rare Diseases, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 601110, China.
  • Department of Neurology, Wuhan No. 1 Hospital, Wuhan, 430033, China.
  • Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Department of Neurology, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China.

Förderung

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Zitieren

APA

Li, Y., Yang, H., Tan, S., Luo, L., Cao, X., Hu, J., Bu, B., Chang, T., & Li, Z. (2026). Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China. Neurology and Therapy, 15(4), 1973-1992. https://doi.org/10.1007/s40120-026-00977-1

Vancouver

Li Y, Yang H, Tan S, Luo L, Cao X, Hu J, et al. Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China. Neurology and Therapy. 2026;15(4):1973-1992. doi:10.1007/s40120-026-00977-1

BibTeX
@article{Li2026,
  author = {Li, Yue and Yang, Huan and Tan, Song and Luo, Lijun and Cao, Xuebing and Hu, JinQuan and Bu, Bitao and Chang, Ting and Li, Zhijun},
  title = {Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China},
  journal = {Neurology and Therapy},
  year = {2026},
  volume = {15},
  number = {4},
  pages = {1973--1992},
  doi = {10.1007/s40120-026-00977-1}
}
Kostenlos starten →